The World Health Organization has resumed the approval procedure for Russia’s Sputnik V COVID-19 vaccine, according to the Russian Direct Investment Fund.
The WHO press service told on September 27 that it was waiting for additional information about Sputnik V from Moscow and only after this data was considered it would be possible to organize an inspection trip to Russia by international experts. In early October, the WHO said that the listing process for the Russian jab was “put on hold,” but will be “sorted out quite soon.”
Now, as the RDIF CEO, Kirill Dmitriev, mentioned in his interview with CNN, WHO experts were expected in Russia soon, so he was hopeful Sputnik V would be approved by the WHO within the next two months. Currently, the world’s first registered COVID-19 vaccine, Sputnik V, with over 91.6 per cent efficacy is authorised for use in 70 countries.
In addition to this piece of good news, another interesting study has appeared in scientific circles, Sputnik reports. As noted by the scientists, mRNA vaccines provide a high peak antibody response against COVID-19 but lose most of their efficacy within 6 months, while human adenoviral vector vaccines provide stable protection levels within 8 months after vaccination.
The results of the American research were echoed by another recent study from Argentina. Argentinian scientists have concluded that Sputnik V, which is based on a human adenoviral vector, provides antibody “maturation” and increased protection against the coronavirus within a 6-month period.